Truist Financial Sticks to Its Hold Rating for Organogenesis Holdings (ORGO)

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Truist Financial analyst Ravi Misra maintained a Hold rating on Organogenesis Holdings (ORGO) with a $2.00 price target, following the stock's close at $1.89. The analyst consensus also reflects a Hold rating with an average target of $2.00.

In a report released on August 11, Ravi Misra from Truist Financial maintained a Hold rating on Organogenesis Holdings, with a price target of $2.00. The company’s shares closed yesterday at $1.89.

Claim 55% Off TipRanks

  • Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
  • Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

According to TipRanks, Misra is an analyst with an average return of -10.7% and a 35.00% success rate. Misra covers the Healthcare sector, focusing on stocks such as Organogenesis Holdings, OrthoPediatrics, and Integra Lifesciences.

Currently, the analyst consensus on Organogenesis Holdings is a Hold with an average price target of $2.00.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.